Harvard Stem Cell Institute (HSCI) Co-director Douglas Melton, PhD, and Evotec AG have entered into their second research collaboration to find biological pathways and signals that could be therapeutically relevant to diabetic patients.
The objective of this new collaboration, dubbed “TargetEEM” (Target Enteroendocrine Mechanisms), is to screen disease-relevant animal models for novel pathways and targets that have the potential to repair mechanisms involved in insulin resistance and abnormal...
Read more about HSCI co-director Douglas Melton and Evotec collaborate on diabetes